127 products were found matching "GeneID 255738"!

Alirocumab, also known as REGN 727, is a recombinant monoclonal antibody that targets PCSK9 (proprotein convertase subtilisin/kexin type 9). It increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation and is used in...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations...

Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9. Useful as a control inhibitor of PCSK9-LDLR binding using the PCSK9 (biotinylated)-LDLR-Binding Assay Kit, Cat. # BPS-72002.

Proprotein convertase subtilisin kexin 9 (PCSK9) is a member of the subtilisin serine protease family with an important role in lipoprotein metabolism. Mutation in the PCSK9 gene is associated with autosomal dominant hypercholesterolemia which is characterized by an increase in low density lipoprotein (LDL)...

Protein Construction: Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9 is produced by our Mammalian expression system and the target gene encoding Gln31-Gln152&Ser153-Gln692 is expressed with a 6His tag at the C-terminus. Sequence: Gln31-Gln152&Ser153-Gln692. Fusion tag: C-6His Endotoxin: < 1.0 EU per...

Proprotein convertase subtilisin kexin 9 (PCSK9) is a zymogen and member of the subtilisin serine protease family that reduces protein levels of LDL receptors (LDLRs), the receptor for LDL-cholesterol (LDL-C). It is primarily expressed in the liver and is composed of an N-terminal prodomain that regulates PCSK9...

Human proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as FH3, HCHOLA3, and PC9, GenBank Accession No. NM_174936, a.a. 31-692(end), with C-terminal His and Avi tags, MW=73.8 kDa (calculated), expressed in an HEK293 cell expression system and enzymatically biotinylated using Avitag(TM) technology.

Human proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as FH3, HCHOLA3, and PC9, GenBank Accession No. NM_174936, a.a. 31-692(end), with C-terminal His and Avi tags, MW=73.8 kDa (calculated), expressed in an HEK293 cell expression system and enzymatically biotinylated using AvitagT technology.

PCSK9 is a member of the subtilisin serine protease family with an important role in low-density lipoprotein (LDL) metabolism. Mutation in the PCSK9 gene is associated with autosomal dominant hypercholesterolemia which is characterized by an increase in LDL cholesterol levels. PCSK9 overexpression in wild-type mice...

Proprotein convertase subtilisin kexin 9 (PCSK9) is a zymogen and member of the subtilisin serine protease family that reduces protein levels of LDL receptors (LDLRs), the receptor for LDL-cholesterol (LDL-C). It is primarily expressed in the liver and is composed of an N-terminal prodomain that regulates PCSK9...

The PCSK9(Biotinylated)-LDLR Binding Assay Kit is designed for screening and profiling purposes. PCSK9 is known to function as a negative regulator of hepatic low-density lipoprotein receptors (LDLRs) by binding to the LDLR ectodomain. The PCSK9(Biotinylated)-LDLR Binding Assay Kit comes in a convenient 96-well...

The PCSK9/LDLR TR-FRET Assay Kit is designed to measure the inhibition of PCSK9 binding to LDLR in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and...